Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Lin H, Jiang J, Liang X et al.
Cetuximab is an inhibitor of EGFR that has been tested in a number of randomized clinical studies, which have reported conflicting results. This meta-analysis was conducted in order to summarize the results of these trials and provide further evidence concerning the role of cetuximab in NSCLC.